“I was also surprised as to the prioritization o
Post# of 148110
(Total Views: 671)
Posted On: 05/16/2024 4:11:33 PM
“I was also surprised as to the prioritization of CRC. I don't remember discussion of this form of cancer in previous PR's. Is there a reason that LL might be more efficacious in treatment of this cancer? Has new information come to light?”
This is a chew well before swallowing article that is highly suggestive CCR5 blockade may be useful for CRC:
“ In conclusion, our comprehensive analysis shows that CCR5 and CCL5 expression identifies a distinct subset of patients with CRC that displays unique tumor molecular features, gene expression profiles and TME cell infiltration, and derive differential benefit from anticancer treatment depending on biologic agent, chemotherapy backbone and primary tumor side. These findings strongly suggest that targeting the CCR5/CCL5 axis may have relevant clinical applications in selected CRC subgroups and support the use of strategies to counteract the CCL5/CCR5 axis to modulate the immune TME for CRC treatment.”
https://jitc.bmj.com/content/12/1/e007939
Directly related, this linked commentary was just published on line May 7, 2024:
https://jitc.bmj.com/content/12/5/e008722
“These authors showed that CCR/L5 expression was both prognostic and predictive. They reported that low expression of the CCR/L5 axis was correlated with improved survival broadly, with particular benefit in patients treated with chemotherapy plus cetuximab. They demonstrated that high expression of CCR/L5 was associated with infiltration by negatively prognostic Tregs, M1 and M2 macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts. They also showed that increased expression was correlated a wide variety of immune suppressive proteins, including PD-1, PD-L1, PD-L2, CTLA4, CD80, CD86, TIM3, IDO1, LAG3, and IFN-γ. This suggests mechanisms by which CRC resists anti-cancer immune responses.”
Leronlimab: “Put me in coach!” Like Nikola Jokić, a freak of nature that can do amazing things once in the game.
This is a chew well before swallowing article that is highly suggestive CCR5 blockade may be useful for CRC:
“ In conclusion, our comprehensive analysis shows that CCR5 and CCL5 expression identifies a distinct subset of patients with CRC that displays unique tumor molecular features, gene expression profiles and TME cell infiltration, and derive differential benefit from anticancer treatment depending on biologic agent, chemotherapy backbone and primary tumor side. These findings strongly suggest that targeting the CCR5/CCL5 axis may have relevant clinical applications in selected CRC subgroups and support the use of strategies to counteract the CCL5/CCR5 axis to modulate the immune TME for CRC treatment.”
https://jitc.bmj.com/content/12/1/e007939
Directly related, this linked commentary was just published on line May 7, 2024:
https://jitc.bmj.com/content/12/5/e008722
“These authors showed that CCR/L5 expression was both prognostic and predictive. They reported that low expression of the CCR/L5 axis was correlated with improved survival broadly, with particular benefit in patients treated with chemotherapy plus cetuximab. They demonstrated that high expression of CCR/L5 was associated with infiltration by negatively prognostic Tregs, M1 and M2 macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts. They also showed that increased expression was correlated a wide variety of immune suppressive proteins, including PD-1, PD-L1, PD-L2, CTLA4, CD80, CD86, TIM3, IDO1, LAG3, and IFN-γ. This suggests mechanisms by which CRC resists anti-cancer immune responses.”
Leronlimab: “Put me in coach!” Like Nikola Jokić, a freak of nature that can do amazing things once in the game.
(14)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼